Table 1 IC50 values and fold increase in drug resistance of parental vs. drug-resistant cells

From: Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma

Drugs

Huh-7 P

Huh-7 LR

Huh-7 SR

IC50 (μM)

IC50 (μM)

Resistant Index

IC50 (μM)

Resistant Index

Lenvatinib

13.02 ± 0.73

50.61 ± 4.62

3.89 ± 0.42

33.52 ± 2.10

2.57 ± 0.22

Sorafenib

6.78 ± 0.13

21.06 ± 0.66

3.11 ± 0.11

16.70 ± 1.15

2.46 ± 0.18

Regorafenib

6.40 ± 0.24

8.53 ± 0.59

1.33 ± 0.11

10.31 ± 0.40

1.61 ± 0.09

Gefitinib

13.78 ± 0.55

25.37 ± 2.70

1.84 ± 0.21

22.43 ± 1.37

1.63 ± 0.12

Lapatinib

14.13 ± 0.51

18.78 ± 0.75

1.32 ± 0.07

25.47 ± 1.15

1.80 ± 0.09

5-Fluorouracil

25.19 ± 1.64

42.74 ± 3.58

1.70 ± 0.18

37.31 ± 2.61

1.48 ± 0.13

Irinotecan

24.54 ± 1.44

22.00 ± 1.43

0.90 ± 0.08

40.76 ± 3.72

1.66 ± 0.18

Oxaliplatin

39.98 ± 1.60

59.25 ± 4.59

1.48 ± 0.13

79.75 ± 4.39

1.99 ± 0.12